“On behalf of the AWG I would like to thank Jeff for his leadership over the past two years,” said Dr. Evan Loh, incoming chairman. “Jeff has been an integral part of AWG since the coalition’s inception in 2012 and has worked tirelessly to advance AWG’s mission of improving the regulatory, investment, and commercial environment...
Author: @admin
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies READ FULL TEXT
SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors
SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors READ FULL TEXT
Antimicrobials Working Group Announces Updates to Leadership Team
WASHINGTON, Jan. 17, 2019 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. Dr. Loh replaces Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara Therapeutics, whose two-year term as Chairman of AWG has expired. Dr. Stein...
Antimicrobials Working Group Announces Updates to Leadership Team
WASHINGTON, Jan. 17, 2019 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. Dr. Loh replaces Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara Therapeutics, whose two-year term as Chairman of AWG has expired. Dr. Stein...
Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on January 23, 2019
DUBLIN, Ireland , Jan. 15, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, today announced that the Company will webcast its Analyst READ FULL TEXT
Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™
-PDUFA action date now set for April 30, 2019- DUBLIN, Ireland , Jan. 14, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced READ FULL TEXT
Award of Restricted Stock Units
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) READ FULL TEXT